cannabidiol-dimethyl-ether and cannabidiolic-acid

Considerable attention has focused on cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, and it has been reported to possess diverse biological activities. Although CBD is obtained from non-enzymatic decarboxylation of its parent molecule, cannabidiolic acid (CBDA), several studies have investigated whether CBDA itself is biologically active. In the present report, the author summarizes findings indicating that; 1) CBDA is a selective cyclooxygenase-2 (COX-2) inhibitor, and ii) CBDA possesses an anti-migrative potential for highly invasive cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. Further, the author introduces recent findings on the medicinal chemistry and pharmacology of the CBD derivative, CBD-2',6'-dimethyl ether (CBDD), that exhibits inhibitory activity toward 15-lipoxygenase (15-LOX), an enzyme responsible for the production of oxidized low-density lipoprotein (LDL). These studies establish CBD as both an important experimental tool and as a lead compound for pharmaceutical development. In this review, the author further discusses the potential uses of CBD and its derivatives in future medicines.

Topics: Animals; Breast Neoplasms; Cannabidiol; Cannabinoids; Cannabis; Cell Movement; Cells, Cultured; Chemistry, Pharmaceutical; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2 Inhibitors; Decarboxylation; Drug Discovery; Female; Humans; Lipoproteins, LDL; Lipoxygenase Inhibitors; Phytotherapy; rhoA GTP-Binding Protein